ASAP Blog

Updated: Friday, September 27, 2019 Andre Turenne began his Wednesday keynote address at the 2019 ASAP BioPharma Conference , held Sept. 23­–25 in Boston, by reminding everyone why biopharma companies form partnerships in the first place: to more effectively find and create new... Continue Reading

Updated: Friday, September 27, 2019 A perennial topic of interest in the ASAP biopharma community—and alliance management in general—revolves around plotting one’s career path and changing jobs, whether that means moving to a new company or shifting to a new job in one’s... Continue Reading

“We see at the highest levels of business and government what happens when we don’t maintain and preserve alliances.” Such was the plain, blunt statement of Rob Bazemore, president and CEO of Epizyme, Inc., Tuesday’s keynote speaker at the 2019 ASAP BioPharma Conference,... Continue Reading

Perhaps one of the less appreciated and less understood roles in biopharma alliances—particularly codevelopment, cocommercial alliances—is that of the medical affairs team, specifically medical science liaisons (MSLs). These field-level folks implement a medical affairs plan and... Continue Reading

Nontraditional alliances took center stage (literally) yet again today as the opening session at the ASAP BioPharma Conference 2019 got under way in Boston. Titled “Building Value in Non-Traditional Pharma/Biotech Partnerships: BMS and Concerto Health AI,” the session was moderated by... Continue Reading

Even a year or two ago, the idea of digital therapeutics didn’t stir up a great amount of interest among most participants at ASAP’s BioPharma Conference, according to Mike Leonetti, president and CEO of ASAP. That sort of ambivalence no longer applies, as was evident at the September... Continue Reading